Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. OBJECTIVE: To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. DESIGN: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). SETTING: University hospital. PARTICIPANTS: Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics. INTERVENTION: All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment. MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. Secondary outcomes included other histologic outcomes, hepatic triglyceride content measured by magnetic resonance and proton spectroscopy, and metabolic parameters. RESULTS: Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each). Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039); reduced hepatic triglyceride content from 19% to 7% (treatment difference, -7 percentage points [CI, -10 to -4 percentage points]; P < 0.001); and improved adipose tissue, hepatic, and muscle insulin sensitivity (P < 0.001 vs. placebo for all). All 18-month metabolic and histologic improvements persisted over 36 months of therapy. The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo). LIMITATION: Single-center study. CONCLUSION: Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and NASH. PRIMARY FUNDING SOURCE: Burroughs Wellcome Fund and American Diabetes Association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefi cial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been seen with pioglitazone (200,201).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“weight gain was also significantly higher in the treatment group [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“a randomized controlled trial including 101 patients with either pre‐ or type 2 diabetes found that 51% in the Pioglitazone group (45 mg/day) had resolution of NASH and 58% achieved the primary outcome of the study (reduction of ≥2 NAS points in two histologic categories without worsening of fibrosis), both significantly [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“Pioglitazone treatment was also associated with a significant improvement in fibrosis score.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“5) mg/dL 149 (36) 153 (34) 1 (−18 to 19) LDL cholesterol level 0.”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 3×
“Additional secondary outcomes included the following: 1) fasting plasma glucose, fasting plasma insulin, FFA, hemoglobin A1c, fasting plasma lipid profile, adiponectin, and cytokeratin-18 concentrations; 2) total body fat percentage, measured by DXA; 3) hepatic triglyceride content, measured by magnetic resonance and…”
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“001 Fibrosis ≥1-point improvement, n (%) 13 (25) 20 (39) 14 (−6 to 34) 0.”
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Research works printed but not linked: 1
- Bril F, 2015, Diabetes, 64, A337
Cited by
Items 301–400 of 1,001
Lee, C., Seto, W., Lui, D. T. W., Fong, C. H.-Y., Wan, H. Y., Cheung, C. Y. Y., Chow, W.-S., Woo, Y. C., Yuen, M., Xu, A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0131 · Cited by 53
Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement
Boursier, J., Anty, R., Carette, C., Cariou, B., Castéra, L., Caussy, C., Fontaine, H., Garioud, A., Gourdy, P., Guerci, B., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101272 · Cited by 55
The therapeutic landscape of non‐alcoholic steatohepatitis
Perazzo, H., & Dufour, J. (2017) · Liver International · doi:10.1111/liv.13270 · Cited by 49
Treatment of type 2 diabetes mellitus in elderly patients
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.12.004 · Cited by 54
MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
Colca, J. R., McDonald, W. G., & Adams, W. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1494153 · Cited by 49
Documento de abordaje integral de la diabetes tipo 2
Reyes‐García, R., Moreno, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Escalada, J., et al. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.10.010 · Cited by 59
Shen, L., Saviano, A., Erstad, D. J., Hoshida, Y., Fuchs, B. C., Baumert, T. F., & Tanabe, K. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123817 · Cited by 57
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Wijarnpreecha, K., Aby, E. S., Ahmed, A., & Kim, D. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0239 · Cited by 59
Lipid metabolism in homeostasis and disease
Li, Z., Deng, W., Yang, L., Tang, C., Yue, J.-M., Monteiro, O., Baptista‐Hon, D. T., & Li, T. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02357-x · Cited by 74
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 53
Głuszyńska, P., Lemancewicz, D., Dzięcioł, J. B., & Hady, H. R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245721 · Cited by 56
“Pioglitazone treatment was also associated with improvement in individual histological scores, including the fibrosis score, reducing hepatic triglyceride content from 19% to 7%, and improving adipose tissue, hepatic, and muscle insulin sensitivity [69].”
BackgroundShared Mechanisms between Cardiovascular Disease and NAFLD
Huang, D. Q., Downes, M., Evans, R. M., Witztum, J. L., Glass, C. K., & Loomba, R. S. (2022) · Seminars in Liver Disease · doi:10.1055/a-1930-6658 · Cited by 47
Sohn, W., Lee, Y., Kim, S. S., Kim, J. H., Jin, Y., Kim, G., Sung, P. S., Yoo, J., Chang, Y. W., Lee, E. J., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0045 · Cited by 75
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
Prat, L. I., & Tsochatzis, E. A. (2018) · HORMONES · doi:10.1007/s42000-018-0021-9 · Cited by 50
Franch‐Nadal, J., Caballería, L., Mata‐Cases, M., Mauricio, D., Giráldez‐García, C., Mancera, J., Goday, A., Mundet, X., Regidor, E., & for the PREDAPS Study Group (2018) · PLoS ONE · doi:10.1371/journal.pone.0198327 · Cited by 51
Chan, W., Tan, S., Chan, S., Lee, Y., Tee, H., Mahadeva, S., Goh, K., Ramli, A. S., Mustapha, F., Kosai, N. R., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15787 · Cited by 46
Fouad, Y. M., Esmat, G., Elwakil, R., Zakaria, S., Yosry, A., Waked, I. A., El-Razky, M., Doss, W. H., El‐Serafy, M., Mostafa, E., et al. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_357_21 · Cited by 54
Nrf2 Pathway and Oxidative Stress as a Common Target for Treatment of Diabetes and Its Comorbidities
Yi, M., Cisneros, L., Cho, E. J., Alexander, M., Kimelman, F. A., Swentek, L., Ferrey, A., Tantisattamo, E., & Ichii, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020821 · Cited by 63
“In a clinical trial of pioglitazone involving patients with NAFLD and either T2D or pre-DM, this drug improved the fibrosis score, reduced triglyceride levels in the liver, and improved adipose tissue, liver, and muscle insulin sensitivity when compared to a placebo [113].”
BackgroundGanguli, S., Deleeuw, P., & Satapathy, S. K. (2019) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s188991 · Cited by 49
“with NASH and pre-diabetes/T2DM confirmed the longterm safety and efficacy of pioglitazone.(58) The PIVENS (Pioglitazone, Vitamin E or Placebo for Nonalcoholic Steatohepatitis (PIVENS) trial was a double-blind, RCT evaluating the efficacy of treatment with Vitamin E, Pioglitazone, or placebo for the treatment of NASH…”
BackgroundPreparing for the NASH Epidemic: A Call to Action
Kanwal, F., Shubrook, J. H., Younossi, Z., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C., Pfotenhauer, K., Klein, S., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0020 · Cited by 45
Self-citationLiver-targeting drugs and their effect on blood glucose and hepatic lipids
Gastaldelli, A., Stefan, N., & Häring, H. (2021) · Diabetologia · doi:10.1007/s00125-021-05442-2 · Cited by 49
Yokota, T., Kinugawa, S., Hirabayashi, K., Suga, T., Takada, S., Omokawa, M., Kadoguchi, T., Takahashi, M., Fukushima, A., Matsushima, S., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12606 · Cited by 49
Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease
Hundertmark, J., Krenkel, O., & Tacke, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02418 · Cited by 44
Lavynenko, O., Abdul‐Ghani, M., Alatrach, M., Puckett, C., Adams, J., Abdelgani, S., Alkhouri, N., Triplitt, C., Clarke, G. D., Vasquez, J. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14650 · Cited by 44
Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers
Basu, R., Noureddin, M., & Clark, J. M. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.04.005 · Cited by 50
The great potential of flavonoids as candidate drugs for NAFLD
Li, L., Qin, Y., Xin, X., Wang, S., Liu, Z., & Feng, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114991 · Cited by 50
Sun, K., Park, J., Kim, M., & Scherer, P. E. (2017) · Diabetologia · doi:10.1007/s00125-016-4130-1 · Cited by 44
Portillo‐Sanchez, P., Bril, F., Lomonaco, R., Barb, D., Orsak, B., Bruder, J. M., & Cusi, K. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12833 · Cited by 43
“Patients treated for 36 months maintained good glycemic control and improved insulin sensitivity, as reported elsewhere.(10) The effect of pioglitazone at different skeletal sites (lumbar spine, hip, and femoral neck) is shown in Fig.”
BackgroundMethodInfluentialSelf-citationConsenso mexicano de la enfermedad por hígado graso no alcohólico
Bernal-Reyes, R., Castro‐Narro, G., Malé-Velázquez, R., Carmona-Sánchez, R., González-Huezo, M. S., García-Juárez, I., Chávez-Tapia, N. C., Aguilar-Salinas, C., Aiza-Haddad, I., Ballesteros-Amozurrutia, M. A., et al. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2018.11.007 · Cited by 71
Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect
Heda, R. P., Yazawa, M., Shi, M. Y., Bhaskaran, M. C., Aloor, F. Z., Thuluvath, P. J., & Satapathy, S. K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1864 · Cited by 50
Shao, S.-C., Kuo, L.-T., Chien, R.-N., Hung, M.-J., & Lai, E. C.-C. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001956 · Cited by 43
Lee, S. M., Muratalla, J. T., Díaz‐Ruiz, A., Remón-Ruiz, P., McCann, M. A., Liew, C. W., Kineman, R. D., & Córdoba‐Chacón, J. (2021) · Endocrinology · doi:10.1210/endocr/bqab175 · Cited by 42
Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update
Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 51
Obeticholic acid for the treatment of nonalcoholic steatohepatitis
Shah, R. A., & Kowdley, K. V. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1748498 · Cited by 47
Ruissen, M. M., Mak, A. L., Beuers, U., Tushuizen, M. E., & Holleboom, A. G. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0065 · Cited by 43
Preparing for the NASH epidemic: A call to action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154822 · Cited by 52
Self-citationMetabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy
Leith, D., Lin, Y. Y., & Brennan, P. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.2 · Cited by 41
Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease
Lee, S. M., Muratalla, J. T., Sierra‐Cruz, M., & Córdoba‐Chacón, J. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0155 · Cited by 49
Rivera‐Esteban, J., Muñoz, S., Higuera, M., Sena, E., Bermúdez-Ramos, M., Bañares, J., Martínez-Gómez, M., Cusidó, M. S., Jiménez-Masip, A., Francque, S., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.028 · Cited by 52
The Immune System in Obesity: Developing Paradigms Amidst Inconvenient Truths
Agrawal, M., Kern, P. A., & Nikolajczyk, B. S. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0917-9 · Cited by 48
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants
Bril, F., Kalavalapalli, S., Lomonaco, R., Frye, R. F., Leiva, E. G., & Cusi, K. J. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101092 · Cited by 49
Self-citationHerath, H. M. M., Kodikara, I., Weerarathna, T. P., & Liyanage, G. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.002 · Cited by 41
Pre-diabetes diagnosis based on ATR-FTIR spectroscopy combined with CART and XGBoots
Yang, X., Fang, T., Li, Y., Liu, G., Li, F., Huang, F., & Li, L. (2018) · Optik · doi:10.1016/j.ijleo.2018.11.059 · Cited by 45
Barritt, A. S., Marshman, E., & Noureddin, M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16794 · Cited by 46
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023) · Nutrients · doi:10.3390/nu15030687 · Cited by 48
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Gu, Y., Sun, L., Zhang, W., Kong, T., Zhou, R., He, Y., Deng, C., Yang, L., Kong, J., Chen, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1102792 · Cited by 50
“Nevertheless, recent research has indicated that weight gain is the most prevalent adverse effect of pioglitazone medication, most likely due to enhanced adipose tissue insulin action and increased adipocyte TG synthesis (Sanyal et al., 2010; Cusi et al., 2016).”
BackgroundSurveillance of the liver in type 2 diabetes: important but unfeasible?
Qadri, S. U., & Yki‐Järvinen, H. (2024) · Diabetologia · doi:10.1007/s00125-024-06087-7 · Cited by 47
Zhang, Y., Liu, X., Zhang, H., & Wang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.836455 · Cited by 47
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
Yoneda, M., Kobayashi, T., Honda, Y., Ogawa, Y., Kessoku, T., Imajo, K., Nogami, A., Taguri, M., Kirikoshi, H., Saito, S., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1993 · Cited by 43
Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
Kruse, B. C., & Vassar, M. B. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.10.007 · Cited by 39
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2017.12.003 · Cited by 47
Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
McCommis, K. S., & Finck, B. N. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.017 · Cited by 39
Managing diabetes and liver disease association
Hamed, A. E., Elsahhar, M., Elwan, N. M., El-Nakeep, S. A. K., Naguib, M., Soliman, H. H., Aboubakr, A. A., Sholkamy, A. A., Sedrak, H. K., Assaad, S. N., et al. (2018) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2018.08.003 · Cited by 47
Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease
Smeuninx, B., Boslem, E., & Febbraio, M. A. (2020) · Cancers · doi:10.3390/cancers12071714 · Cited by 39
“When long-term pioglitazone treatment was combined with a daily 500 kcal dietary deficit, NASH resolution was achieved in 51% of prediabetic and diabetic patients [47].”
BackgroundNAFLD Related-HCC: The Relationship with Metabolic Disorders
Zhang, X. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_5 · Cited by 41
Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis
Ratziu, V., Ghabril, M., Romero-Gomez, M., & Svegliati-Baroni, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002483 · Cited by 38
Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
Xiao, Y., Kim, M., & Lazar, M. A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101119 · Cited by 43
Yan, H., Wu, W., Chang, X., Xia, M., Ma, S., Wang, L., & Gao, J. (2021) · Biology of Sex Differences · doi:10.1186/s13293-020-00344-1 · Cited by 42
Takeda, A., Irahara, A., Nakano, A., Takata, E., Koketsu, Y., Kimata, K., Senda, E., Yamada, H., Ichikawa, K., Fujimori, T., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8754-16 · Cited by 37
“Recently, in a 3-year study (14), 58% of the pioglitazone group showed a decrease of 2 points in the total NAS.”
BackgroundMatsumoto, M., Yashiro, H., Ogino, H., Aoyama, K., Nambu, T., Nakamura, S., Nishida, M., Wang, X., Erion, D. M., & Kaneko, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228212 · Cited by 37
“Despite the significant efforts in clinical development for drug to treat fibrosis and NASH, there is currently no approved drugs to treat these conditions [7, 8].”
BackgroundMills, E. P., Brown, K. P. D., Smith, J. D., Vang, P. W., & Trotta, K. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817741852 · Cited by 41
Colca, J. R., & Scherer, P. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101409 · Cited by 41
Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
Wang, Z., Ye, M., Zhang, X., Zhang, P., Cai, J., Li, H., & She, Z. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.010 · Cited by 40
Gu, Y., Sun, L., He, Y., Yang, L., Deng, C., Zhou, R., Kong, T., Zhang, W., Chen, Y., Li, J., et al. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2172397 · Cited by 36
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks
Cheung, A. C., & Ahmed, A. (2021) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s226130 · Cited by 40
Non-alcoholic fatty liver disease in mice with heterozygous mutation in TMED2
Hou, W., Gupta, S., Beauchamp, M.-C., Yuan, L., & Jerome‐Majewska, L. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182995 · Cited by 40
Yang, H., Suh, D. H., Kim, D., Jung, E. S., Liu, K., Lee, C. H., & Park, C. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14434 · Cited by 38
“TZDs have provided histological benefit by improving steatosis and inflammation in many clinical trials (Promrat et al., 2004; Belfort et al., 2006; Sanyal et al., 2010; Cusi et al., 2016).”
BackgroundMarchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2022) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 35
Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients
Cheung, A. C., Figueredo, C. J., & Rinella, M. E. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000058 · Cited by 41
The Mexican consensus on nonalcoholic fatty liver disease
Bernal-Reyes, R., Castro‐Narro, G., Malé-Velázquez, R., Carmona-Sánchez, R., González-Huezo, M. S., García-Juárez, I., Chávez-Tapia, N. C., Aguilar-Salinas, C., Aiza-Haddad, I., Ballesteros-Amozurrutia, M. A., et al. (2019) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2019.02.003 · Cited by 45
Yan, M., Man, S., Ma, L., & Gao, W. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155264 · Cited by 35
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
Fu, Y., Zhou, Y., Shen, L., Li, X., Zhang, H., Cui, Y., Zhang, K., Li, W., Chen, W., Zhao, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.973366 · Cited by 40
“In addition, the group treated with pioglitazone showed improvement in their fibrosis score, hepatic triglyceride content, and insulin sensitivity (Cusi et al., 2016).”
BackgroundPioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs
Zhao, Y. D., Zhao, W., Wang, H., Zhao, Y., Bu, H., & Takahashi, H. (2022) · Medicine · doi:10.1097/md.0000000000031508 · Cited by 35
“Fasting plasma insulin Cusi([32]) 2016 T:52 ± 10”
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 38
“Pioglitazone has been shown to significantly reduce hepatic steatosis, achieve resolution of NASH, and delay fibrosis progression [54].”
BackgroundSelf-citationIsaacson, R. H., Beier, J. I., Khoo, N. K. H., Freeman, B. Α., Freyberg, Z., & Arteel, G. E. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108399 · Cited by 34
Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review
Castillo, V., Figueroa, F., González-Pizarro, K., Jopia, P., & Ibacache‐Quiroga, C. (2021) · Foods · doi:10.3390/foods10081719 · Cited by 39
Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
Filipović, B. F., Marjanovic-Haljilji, M., Mijac, D. D., Lukić, S., Kapor, S., Kapor, S., Starčević, A., Popovic, D. D., & Djoković, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110573 · Cited by 37
“Pioglitazone showed histological improvement, while the effect on liver fibrosis was not significant in both study groups: patients with T2DM and patients with IR [82,83].”
Xiao, J., Xiang, H., Xiang, H., Sun, Z., Xu, J., Ren, H., Hu, P., & Peng, M. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176113 · Cited by 33
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 42
Bando, Y., Ogawa, A., Ishikura, K., Kanehara, H., Hisada, A., Notumata, K., Okafuji, K., & Toya, D. (2017) · Diabetology International · doi:10.1007/s13340-016-0302-y · Cited by 35
Nonalcoholic steatohepatitis: global impact and clinical consequences
Kabbara, K. W., Golabi, P., & Younossi, Z. M. (2021) · Endocrine Connections · doi:10.1530/ec-21-0048 · Cited by 36
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 38
Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
Alkhouri, N., Poordad, F. F., & Lawitz, E. (2018) · Hepatology Communications · doi:10.1002/hep4.1195 · Cited by 40
“More recently, the effects of pioglitazone on NASH in patients with prediabetes and T2D were evaluated.((20)) Fifty-one percent of patients that received pioglitazone 45 mg daily for 72 weeks had resolution of NASH and improvement in several histologic features, including liver fibrosis.”
BackgroundNAFLD in type 2 diabetes mellitus: Still many challenging questions
Cernea, S., & Raz, I. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3386 · Cited by 38
“lution of NASH, and significant improvement of fibrosis (Table 3).(127,128) The study by Belfort et al.”
BackgroundClinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
Chung, W., Promrat, K., & Wands, J. R. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i9.533 · Cited by 36
Carretero, R. G., Holgado–Cuadrado, R., & Barquero‐Pérez, Ó. (2021) · Entropy · doi:10.3390/e23060763 · Cited by 44
Oligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 35
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 50
Davies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 61
Bajpeyi, S., Pasarica, M., Conley, K. E., Newcomer, B. R., Jubrias, S. A., Gamboa, C., Murray, K. B., Sereda, O., Sparks, L. M., & Smith, S. R. (2016) · Metabolism · doi:10.1016/j.metabol.2016.11.016 · Cited by 33
A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis
Kawaguchi-Suzuki, M., Cusi, K., Bril, F., Gong, Y., Langaee, T., & Frye, R. F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00752 · Cited by 31
Self-citationCórdoba‐Chacón, J. (2020) · PPAR Research · doi:10.1155/2020/9735083 · Cited by 34
Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions
Campbell, P. T., Symonds, A., & Barritt, A. S. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.01.021 · Cited by 34
Arai, T., Atsukawa, M., Tsubota, A., Mikami, S., Ono, H., Kawano, T., Yoshida, Y., Tanabe, T., Okubo, T., Hayama, K., et al. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211000243 · Cited by 32
Lin, C., Adhikary, P., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.008 · Cited by 35
Kamm, D. R., Pyles, K. D., Sharpe, M. C., Healy, L. N., Colca, J. R., & McCommis, K. S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100807 · Cited by 34
Sex-dependent dynamics of metabolism in primary mouse hepatocytes
Hochmuth, L., Körner, C., Ott, F., Volke, D., Cokan, K. B., Juvan, P., Brosch, M., Hofmann, U., Hoffmann, R., Rozman, D., et al. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03118-9 · Cited by 52
Metadata
- Authors
- Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., Webb, A., & Portillo-Sanchez, P.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- From University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida, and University of Texas Health Science Center at San Antonio and Audie L. Murphy Veterans Affairs Medical Center, San Antonio, Texas.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-09-06
- Volume
- 165
- Issue
- 5
- Pages
- 305-315
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2470709274
- Cited by
- 1,024
- References
- 62
- Citations by year
- 2026: 82 · 2025: 108 · 2024: 109 · 2023: 103 · 2022: 116 · 2021: 131 · 2020: 108 · 2019: 85 · 2018: 85 · 2017: 67 · 2016: 27
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- U.S. Department of Veterans Affairs (1 I01 CX000167-01)
- American Diabetes Association
- Burroughs Wellcome Fund
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, nonalcoholic steatohepatitis, prediabetes, type 2 diabetes, long-term treatment, hypocaloric diet, NASH resolution, liver fibrosis, hepatic triglyceride content, insulin sensitivity, insulin resistance, PPARγ agonists, drug safety, adverse events, liver histopathology, hepatic steatosis
- MeSH terms
- Pioglitazone, Transaminases, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Prediabetic State, Triglycerides, Biomarkers, Weight Gain, Thiazolidinediones, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.